To be blunt, many of you posters don't get this technology. The next capital raise along with the license payments will build out a management team. SVF or stromal vascular fraction is a major area of autologous stem cell research. There are many, many clinical trials taking place. This can be a robust business.
I've been in the medical technology business for 30 years; this has significant potential. A win will be all about corporate execution.
Simply don't buy it if you don't feel its worth the investment. Linkedin would hardly seem worth $70 a share either, no patent there, no ground breaking tech, yet there it is LNKD @ $71.00 Go figure. If this market is what they estimate and this ends up being a patented process with good trial results then you guess what its value could be. People come on boards trying to beat up a stock usually with an axe to grind from losing some money or in hopes to pick up a bargain, maybe even sell short if theres panic volume. SVFC being around such a short time the money loss seems unlikely since up until a week ago the price was somewaht consistant. Good luck on your choices.
Its pointless arguing with someone that possibly lost money with a previous business. Could a MM have purchased shares only to sell them off at bid price driving share value down on a lightly traded company, only to mop up all the old media exchange or china shares floating around out there? Gaining a more favorable overall position? For there to be a flurry of volume like yesterday someone that still see a favorable future for this company has to be buying a lot of stock. Seems odd to me that there is no slate of presentations on the web site during this period.